|
|
Blood, 1 July 2004, Vol. 104, No. 1, pp. 184-191.
Prepublished online as a Blood First Edition Paper on March 4, 2004; DOI 10.1182/blood-2003-12-4274.
 Previous Article | Table of Contents | Next Article 
IMMUNOBIOLOGY
TNF-related apoptosis-inducing ligand is involved in neutropenia of systemic lupus erythematosus
Wataru Matsuyama,
Masuki Yamamoto,
Ikkou Higashimoto,
Ken-ichi Oonakahara,
Masaki Watanabe,
Kentarou Machida,
Teizo Yoshimura,
Nobutaka Eiraku,
Masaharu Kawabata,
Mitsuhiro Osame, and
Kimiyoshi Arimura
From the Department of Respiratory Medicine, National Minami-kyushu Hospital and the Third Department of Internal Medicine, Kagoshima University Faculty of Medicine, Kagoshima, Japan; and the Laboratory of Molecular Immunoregulation, National Cancer Institute–Frederick, Frederick, MD.
Neutropenia is a common laboratory finding in systemic lupus erythematosus (SLE). However, the molecular mechanism of SLE neutropenia has not been fully explained. In this study, we examined whether TNF-related apoptosis-inducing ligand (TRAIL) is involved in the pathogenesis of SLE neutropenia using samples from SLE patients. Serum TRAIL levels in SLE patients with neutropenia were significantly higher than those of SLE patients without neutropenia and healthy volunteers. Serum TRAIL levels showed a significant negative correlation with neutrophil counts in SLE patients. The expression of TRAIL receptor 3 was significantly lower in SLE patients with neutropenia than in patients without neutropenia or in healthy volunteers. Treatment with glucocorticoids negated the decrease of TRAIL receptor 3 expression on neutrophils of SLE patients. TRAIL may accelerate neutrophil apoptosis of neutrophils from SLE patients, and autologous T cells of SLE patients, which express TRAIL on surface, may kill autologous neutrophils. Interferon gamma and glucocorticoid modulated the expression of TRAIL on T cells of SLE patients and also modulated the expression of cellular Fas-associating protein with death domain–like interleukin-1 –converting enzyme (FLICE)–inhibitory protein (cFLIP), an inhibitor of death receptor signaling, in neutrophils. Thus, our results provide a novel insight into the molecular pathogenesis of SLE neutropenia.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Neutropenia in systemic lupus erythematosus
- W. Conrad Liles, Gordon Starkebaum, and David C. Dale
Blood 2004 104: 2.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
K.-J. Li, M.-C. Lu, S.-C. Hsieh, C.-H. Wu, H.-S. Yu, C.-Y. Tsai, and C.-L. Yu
Release of surface-expressed lactoferrin from polymorphonuclear neutrophils after contact with CD4+T cells and its modulation on Th1/Th2 cytokine production
J. Leukoc. Biol.,
August 1, 2006;
80(2):
350 - 358.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Cassatella, V. Huber, F. Calzetti, D. Margotto, N. Tamassia, G. Peri, A. Mantovani, L. Rivoltini, and C. Tecchio
Interferon-activated neutrophils store a TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) intracellular pool that is readily mobilizable following exposure to proinflammatory mediators
J. Leukoc. Biol.,
January 1, 2006;
79(1):
123 - 132.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Matsuyama, H. Mitsuyama, M. Watanabe, Y. Shirahama, I. Higashimoto, M. Osame, and K. Arimura
Involvement of Discoidin Domain Receptor 1 in the Deterioration of Pulmonary Sarcoidosis
Am. J. Respir. Cell Mol. Biol.,
December 1, 2005;
33(6):
565 - 573.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M N Lub-de Hooge, E G E de Vries, S de Jong, and M Bijl
Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus
Ann Rheum Dis,
June 1, 2005;
64(6):
854 - 858.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Matsuyama, M. Watanabe, Y. Shirahama, K.-i. Oonakahara, I. Higashimoto, T. Yoshimura, M. Osame, and K. Arimura
Activation of Discoidin Domain Receptor 1 on CD14-Positive Bronchoalveolar Lavage Fluid Cells Induces Chemokine Production in Idiopathic Pulmonary Fibrosis
J. Immunol.,
May 15, 2005;
174(10):
6490 - 6498.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
